Luciferase Antibody (Luci 21 1-107) - BSA Free

Western Blot: Luciferase Antibody (Luci 21 1-107) [NB600-307] - Reduction in CREB activity in flies following DN-CREB expression in the fat body. CRE-Luciferase reporter protein was measured using anti-luciferase antibody in Western blots of body extracts from control flies (to-GAL4 driver only, control) or flies expressing DN-CREB in the fat body from the to-GAL4 driver (DN-CREB) (top panel). Blots were stripped and reprobed with anti-tubulin antibodies as a protein loading control (bottom panel). Signal intensities were quantified and are shown as ratios to control signals (mean+/-SD, n = 5; *p<0.05, Student's t-test). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0008498) licensed under a CC-BY license.

Immunohistochemistry: Luciferase Antibody (Luci 21 1-107) [NB600-307] - Detection of Luciferase expression in CD34+ cells by Immunohistochemistry. Cytospin slides prepared from transduced CD34+ cells after 3 days of culture were stained with monoclonal anti-Luciferase antibody. Luciferase-positive cells have green cytoplasm; nuclei stained with DAPI are blue. Nontransduced, cultured CD34+ cells were used as a negative control. Original magnification, 40X. Wang, X. et al., Dynamic tracking of human hematopoietic stem cell. Blood. 102(10): 3478-3482, 2003.

Western Blot: Luciferase Antibody (Luci 21 1-107) [NB600-307] - WB analysis of NB600-307 on Luciferase Protein (NB810-74573)

Western Blot: Luciferase Antibody (Luci 21 1-107) - BSA Free [NB600-307] - TTFields application leads to increased autophagic flux.a Ultra-structural STEM electron microscopy analysis of U-87 MG (upper panel) & A172 (lower panel) cells treated with TTFields for 48 h. Autophagosomes (blue arrows) & autolysosomes (green arrows) are indicated. b U-87 MG & A172 cells were either left untreated or were treated with TTFields for 24–72 h. CQ (20 µM) was added 4 h before cells were collected. Samples were immunoblotted for LC3 & GAPDH. Upper panel: representative blots. Lower panel: densitometric quantification of immunoblot signal, showing an average of at least three independent experiments (0.01 < *P < 0.05, Student’s t-test). c U-87 MG & A172 cells were either left untreated or were treated with TTFields for 48 h. CQ (20 µM) was added at the last 3 h of treatment & cells were fixed & stained with anti-LC3 Ab (green) & DAPI (blue). Upper panel: representative images. Original magnifications: × 40. Lower panel: quantification of LC3 intensity, presented as average intensity per cell (**P < 0.01, Student’s t-test). d U-87 MG cells were either left untreated or were treated with TTFields (48 h) or with vinblastin 25 nM (0.5 h). CQ (20 µM) was added at the last 3 h of treatment & cells were fixed & stained with anti-LC3 (green), LAMP1 (red), & DAPI (blue) (upper panel). Arrowheads indicate the strongest colocalization staining in each cell. Intensity histograms of LAMP1 & LC3 fluorescent signal calculated from the region of interest indicated by the white bar (lower panel). Representative images are shown Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30341282), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Luciferase Antibody (Luci 21 1-107) - BSA Free [NB600-307] - Induction of autophagy by TTFields is AMPK dependent.a U-87 MG & A172 cells either left untreated or treated w/ TTFields for indicated time points. Immunoblot analysis of GFP78 protein. Numeric values represent fold increase in GRP78 signal, normalized to loading control (GAPDH), relative to untreated control. b Quantification of intracellular ATP levels in U-87 MG cells either left untreated or treated w/ TTFields for 72 h.Results presented as average ATP concentration (nmol/2 × 106 cells) from 3 independent experiments (*P < 0.01, Student’s t-test). c U-87 MG & A172 cells either left untreated or treated w/ TTFields for indicated time points. Immunoblot analysis of pAMPK & pULK1proteins. GAPDH used as loading control. (5D-F) U-87 MG cells transfected w/ AMPK-targeting siRNA (siAMPK) or w/ siRNA sham vector (siVector), & incubated for 48 h w/ or w/out TTFields application. CQ 20 µM added for last 4 h of treatment where indicated. d (left panel) Immunoblot analysis of LC3 & AMPK. Numeric values represent fold-change in LC3-II signal, normalized to GAPDH signal, relative to respective control. d (right panel) CQ-treated cells fixed & stained for LC3 (green) & DAPI (blue), original magnifications: × 40. e Cell count of siAMPK- or siVector-expressing cells after TTFields treatment. (0.01 < *P < 0.05, Student’s t-test, n = 3). f siVector- & siAMPK-transfected U-87 MG cells either left untreated or treated w/ TTFields for 48 h. Cells then fixed & stained for cleaved caspase-3 (green) & DAPI (blue) (left panel). Images from each treatment analyzed manually & fraction of cleaved caspase-3-positive cells calculated for at least 200 cells from each group (right panel) (**P < 0.01, Student’s t-test, n = 2) Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/30341282), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Luciferase Antibody (Luci 21 1-107) - BSA Free [NB600-307] - TTFields induce autophagy in glioma cell lines.a U-87 MG & A172 cells were either left untreated or treated with TTFields at the last 24 h, 48 h, or 72 h of culturing. All cultures were plated on the same time, incubated overnight to allow cell attachment, & collected 72 h afterwards. Cells were collected, lysed, & samples were analyzed using immunoblotting for LC3 & GAPDH. Upper panel: representative blots. Lower panel: densitometric quantification of immunoblot signal, showing an average of at least three independent experiments (0.01 < *P < 0.05, **P < 0.01, Student’s t-test). b Paraffin-embedded sections from sham- or TTFields-treated rats were stained with anti-LC3 Ab (green) & DAPI (blue). Representative images are presented. c Quantification of LC3 intensity, presented as fold increase from corresponding control (*P < 0.05, Student’s t-test) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30341282), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Luciferase Antibody (Luci 21 1-107) - BSA Free [NB600-307] - Immunofluorescence imaging of luciferase protein as a reporter of hybrid formation. Entire primary tumor & lung sections were imaged via tile scanning, & each image of the scan was carefully analyzed to confirm or refute positive staining for luciferase. The luciferase signal was considered a positive signal if it was above background levels associated with negative controls & corresponded to the cytoplasm of a cell with a nucleus. Rare luciferase-positive cells were detected in the primary tumors. Most red signal was not in the cytoplasm of cells associated with nuclei and, therefore, considered nonspecific [insets (a), (c)]. The lungs containing metastases on the other hand [(b), (d)] contained a large number of bona fide luciferase-positive cells corresponding to fusion products. Scale bars on slide scans = 100 μm. Scale bars on 40× inset = 25 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31069316), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Luciferase Antibody (Luci 21 1-107) - BSA Free [NB600-307] - TTFields induce autophagy in glioma cell lines.a U-87 MG & A172 cells were either left untreated or treated with TTFields at the last 24 h, 48 h, or 72 h of culturing. All cultures were plated on the same time, incubated overnight to allow cell attachment, & collected 72 h afterwards. Cells were collected, lysed, & samples were analyzed using immunoblotting for LC3 & GAPDH. Upper panel: representative blots. Lower panel: densitometric quantification of immunoblot signal, showing an average of at least three independent experiments (0.01 < *P < 0.05, **P < 0.01, Student’s t-test). b Paraffin-embedded sections from sham- or TTFields-treated rats were stained with anti-LC3 Ab (green) & DAPI (blue). Representative images are presented. c Quantification of LC3 intensity, presented as fold increase from corresponding control (*P < 0.05, Student’s t-test) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30341282), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Luciferase Antibody (Luci 21 1-107) - BSA Free [NB600-307] - TTFields application leads to increased autophagic flux.a Ultra-structural STEM electron microscopy analysis of U-87 MG (upper panel) & A172 (lower panel) cells treated with TTFields for 48 h. Autophagosomes (blue arrows) & autolysosomes (green arrows) are indicated. b U-87 MG & A172 cells were either left untreated or were treated with TTFields for 24–72 h. CQ (20 µM) was added 4 h before cells were collected. Samples were immunoblotted for LC3 & GAPDH. Upper panel: representative blots. Lower panel: densitometric quantification of immunoblot signal, showing an average of at least three independent experiments (0.01 < *P < 0.05, Student’s t-test). c U-87 MG & A172 cells were either left untreated or were treated with TTFields for 48 h. CQ (20 µM) was added at the last 3 h of treatment & cells were fixed & stained with anti-LC3 Ab (green) & DAPI (blue). Upper panel: representative images. Original magnifications: × 40. Lower panel: quantification of LC3 intensity, presented as average intensity per cell (**P < 0.01, Student’s t-test). d U-87 MG cells were either left untreated or were treated with TTFields (48 h) or with vinblastin 25 nM (0.5 h). CQ (20 µM) was added at the last 3 h of treatment & cells were fixed & stained with anti-LC3 (green), LAMP1 (red), & DAPI (blue) (upper panel). Arrowheads indicate the strongest colocalization staining in each cell. Intensity histograms of LAMP1 & LC3 fluorescent signal calculated from the region of interest indicated by the white bar (lower panel). Representative images are shown Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30341282), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Luciferase Antibody (Luci 21 1-107) - BSA Free [NB600-307] - TTFields application leads to increased autophagic flux.a Ultra-structural STEM electron microscopy analysis of U-87 MG (upper panel) & A172 (lower panel) cells treated with TTFields for 48 h. Autophagosomes (blue arrows) & autolysosomes (green arrows) are indicated. b U-87 MG & A172 cells were either left untreated or were treated with TTFields for 24–72 h. CQ (20 µM) was added 4 h before cells were collected. Samples were immunoblotted for LC3 & GAPDH. Upper panel: representative blots. Lower panel: densitometric quantification of immunoblot signal, showing an average of at least three independent experiments (0.01 < *P < 0.05, Student’s t-test). c U-87 MG & A172 cells were either left untreated or were treated with TTFields for 48 h. CQ (20 µM) was added at the last 3 h of treatment & cells were fixed & stained with anti-LC3 Ab (green) & DAPI (blue). Upper panel: representative images. Original magnifications: × 40. Lower panel: quantification of LC3 intensity, presented as average intensity per cell (**P < 0.01, Student’s t-test). d U-87 MG cells were either left untreated or were treated with TTFields (48 h) or with vinblastin 25 nM (0.5 h). CQ (20 µM) was added at the last 3 h of treatment & cells were fixed & stained with anti-LC3 (green), LAMP1 (red), & DAPI (blue) (upper panel). Arrowheads indicate the strongest colocalization staining in each cell. Intensity histograms of LAMP1 & LC3 fluorescent signal calculated from the region of interest indicated by the white bar (lower panel). Representative images are shown Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30341282), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Pp
• Applications: WB, Flow, ICC/IF, IHC
• Clone: Luci 21 1-107
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

Luciferase Antibody (Luci 21 1-107) - BSA Free Summary

• Immunogen: This Luciferase Antibody (Luci 21 1-107) was developed against luciferase protein from Photinus pyralis (North American firefly). [UniProt# P08659].
• Localization: Peroxisome
• Specificity: This Luciferase Antibody (Luci 21 1-107) is specific for Luciferase, recognizing a peptide consisting of the first 258 amino acids. Further epitope mapping has not been done at this time.
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:200. Use reported by customer review
  • Immunocytochemistry/ Immunofluorescence 1:100-1:1000
  • Immunohistochemistry 1:100-1:1000
  • Immunohistochemistry-Frozen reported in scientific literature (PMID 31069316)
  • Immunohistochemistry-Paraffin 1:100-1:1000
  • Western Blot 1:1000
• Application Notes: Western blot has been tested with Drosophila embryos. Purified Luciferase protein and Luciferase expressed in Drosophila adult co-migrate on Western blots with a band seen at ~61 kDa, representing Luciferase.

Reactivity Notes

Photinus pyralis (North American firefly).

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein A or G purified

Alternate Names for Luciferase Antibody (Luci 21 1-107) - BSA Free

• ec 1.13.12.7
• firefly luciferase
• Fluc
• LuC
• Luciferase
• luciferin 4 monooxygenase
• Luciferin 4-monooxygenase

Background

Luciferase is a generic term for a group of oxidative enzymes used in bioluminescence. Firefly (Photinus pyralis) and bacterial luciferase enzymes are commonly used in assay systems such as cell viability assays, reporter gene assays, and for in vivo imaging. Bacterial luciferases are flavoenzymes composed of two subunits each encoded by the luxA and luxB genes, while the firefly luciferase is a single polypeptide specified by the luc gene (1). Firefly luciferase (theoretical molecular weight: 61 kDa) oxidizes the substrate luciferin to oxyluciferin in a bioluminescent reaction requiring Mg2+ and ATP (2,3). This reaction produces a flash of yellow-green light with an emission peak around 560nm that can be detected by a luminometer (3). Firefly luciferase has become one of the more widely used reporter proteins and is an excellent tool for the study of gene expression, given that the amount of light emitted is directly proportional to luciferase activity (4).

The luciferase assay is fast and sensitive, differentiating itself from the CAT (chloramphenicol acetyltransferase) assay because it does not require a radioactive substrate.

References

1. Eun, H. (1996). Marker/Reporter enzymes. Enzymology Primer for Recombinant DNA Technology, 567-645. doi:10.1016/b978-012243740-3/50011-9

2. McNabb, D. S., Reed, R., & Marciniak, R. A. (2005). Dual luciferase assay system for rapid assessment of gene expression in Saccharomyces cerevisiae. Eukaryotic Cell, 4(9), 1539-1549. doi:10.1128/ec.4.9.1539-1549.2005

3. Fraga, H. (2008). Firefly luminescence: A historical perspective and recent developments. Photochemical & Photobiological Sciences, 7(2), 146-158. doi:10.1039/b719181b

4. Younes, A., Lukyanenko, Y. O., Lyashkov, A. E., Lakatta, E. G., & Sollott, S. J. (2011). A bioluminescence method for direct measurement of phosphodiesterase activity. Analytical Biochemistry, 417(1), 36-40. doi:10.1016/j.ab.2011.05.036

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Luciferase Antibody (NB600-307)(29)

Publications using NB600-307

• Dadi Jiang, Youming Guo, Tianyu Wang, Liang Wang, Yuelong Yan, Ling Xia, Rakesh Bam, Zhifen Yang, Hyemin Lee, Takao Iwawaki, Boyi Gan, Albert C Koong IRE1 alpha determines ferroptosis sensitivity through regulation of glutathione synthesis. Nature communications 2024-05-15 [PMID: 38750057]
• Huiyun Li, Yusong Yuan, Lingpu Zhang, Chun Xu, Hailin Xu, Zhiwei Chen Reprogramming Macrophage Polarization, Depleting ROS by Astaxanthin and Thioketal-Containing Polymers Delivering Rapamycin for Osteoarthritis Treatment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023-12-14 [PMID: 38093659]
• Masroni, MSB;Lee, KW;Lee, VKM;Ng, SB;Law, CT;Poon, KS;Lee, BT;Liu, Z;Tan, YP;Chng, WL;Tucker, S;Ngo, LS;Yip, GWC;Nga, ME;Hue, SSS;Putti, TC;Bay, BH;Lin, Q;Zhou, L;Hartman, M;Loh, TP;Lakshmanan, M;Lee, SY;Tergaonkar, V;Chua, H;Lee, AVH;Yeo, EYM;Li, MH;Chang, CF;Kee, Z;Tan, KM;Tan, SY;Koay, ES;Archetti, M;Leong, SM; Dynamic altruistic cooperation within breast tumors Molecular cancer 2023-12-14 [PMID: 38093346]
• Sasaki L, Hamada Y, Yarimizu D et al. Intracrine activity involving NAD-dependent circadian steroidogenic activity governs age-associated meibomian gland dysfunction Nature Aging 2022-02-01 [PMID: 37117756] (IHC-P)
• Tatangelo V, Boncompagni G, Capitani N et al. p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-?B Frontiers in Oncology 2022-06-29 [PMID: 35847884] (Immunocytochemistry/ Immunofluorescence, Firefly)
• Westendorf K, �entelis S, Wang L et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants Cell Reports 2022-05-01 [PMID: 35568025]
• Westendorf K, Zentelis S, Wang L et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants bioRxiv [PMID: 33972947]
• Vara-P�rez M, Rossi M, Van den Haute C et al. BNIP3 promotes HIF-1?-driven melanoma growth by curbing intracellular iron homeostasis The EMBO Journal 2021-05-17 [PMID: 33932034] (Immunocytochemistry/ Immunofluorescence, Firefly)
• Yu CI, Martinek J, Wu TC et al. Human KIT+ myeloid cells facilitate visceral metastasis by melanoma The Journal of experimental medicine 2021-06-07 [PMID: 33857287] (Mouse)
• Cheng YC, Chiang HY, Cheng SJ et al. Loss of the tumor suppressor BTG3 drives a pro-angiogenic tumor microenvironment through HIF-1 activation Cell death & disease 2020-12-11 [PMID: 33311481] (IF/IHC)
• Bin Yu, Shoeb Ikhlas, Chunsheng Ruan, Xingxing Zhong, Dongsheng Cai Innate and Adaptive Immunity of Murine Neural Stem Cell-Derived piRNA Exosomes/Microvesicles against Pseudotyped SARS-CoV-2 and HIV-Based Lentivirus iScience 2020-11-13 [PMID: 33205008]
• Law EK, Levin-Klein R, Jarvis MC et al. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo Journal of Experimental Medicine 2020-12-07 [PMID: 32870257] (Immunocytochemistry/ Immunofluorescence, Firefly)
• Chitwood, C A, Dietzsch, C Et al. Breast tumor cell hybrids form spontaneously in vivo and contribute to breast tumor metastases. APL Bioeng 2018-09-01 [PMID: 31069316] (IF/IHC)
• Shteingauz A, Porat Y, Voloshin T et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields) Cell Death Dis 2018-10-19 [PMID: 30341282] (IF/IHC, ICC/IF, WB)
• Galisova A, Herynek V, Swider E et al. A Trimodal Imaging Platform for Tracking Viable Transplanted Pancreatic Islets In Vivo: F-19 MR, Fluorescence, and Bioluminescence Imaging. Mol Imaging Biol 2018-08-30 [PMID: 30167995] (IHC-P, Firefly)
• Cunningham D, Zhang Q, Liu S, et al. Interleukin-17 promotes metastasis in an immunocompetent orthotopic mouse model of prostate cancer Am J Clin Exp Urol 2018-07-25 [PMID: 30038943] (IHC-P)
• Sayed D, Yang Z, He M, et al. Acute targeting of general transcription factor IIB restricts cardiac hypertrophy via selective inhibition of gene transcription Circ Heart Fail 2014-11-16 [PMID: 25398966] (WB)
• Wang K, Liu S, Wang J et al. Transcriptional regulation of human USP24 gene expression by NF-kappa B. J Neurochem. 2013-11-29 [PMID: 24286619] (WB)
• Schmeisser MJ, Baumann B, Johannsen S, et al. IkappaB kinase/nuclear factor kappaB-dependent insulin-like growth factor 2 (Igf2) expression regulates synapse formation and spine maturation via Igf2 receptor signaling J Neurosci 2012-04-20 [PMID: 22514330] (ICC/IF)
• Li JF, Bush J, Xiong Y et al. Large-scale protein-protein interaction analysis in Arabidopsis mesophyll protoplasts by split firefly luciferase complementation. PLoS One 2011-01-01 [PMID: 22096563] (WB, Firefly)
• Iijima K, Zhao L, Shenton C, Iijima-Ando K. Regulation of energy stores and feeding by neuronal and peripheral CREB activity in Drosophila. PLoS One;4(12):e8498. 2009-12-30 [PMID: 20041126] (WB)
• Chinta, SJ et al. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci;27(51):13997-4006. 2007-12-19 [PMID: 18094238]
• Love Z, Wang F, Dennis J et al. Imaging of mesenchymal stem cell transplant by bioluminescence and PET. J Nucl Med;48(12):2011-20. 2007-12-01 [PMID: 18006616] (IF/IHC, Firefly)
• Wilber A, Linehan JL, Tian X et al. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells 2007-11-01 [PMID: 17673526] (ICC/IF)
• Tang X, Molina M, Amar S. p53 short peptide (p53pep164) regulates lipopolysaccharide-induced tumor necrosis factor-alpha factor/cytokine expression. Cancer Res. 2007-02-01 [PMID: 17283168] (Firefly)
• Aleksic, T et al. Cellular immune reaction in the pancreas is induced by constitutively active IkappaB kinase-2. Gut;56(2):227-36. 2007-02-01 [PMID: 16870717]
• Zhou, W et al. Leaky scanning and reinitiation regulate BACE1 gene expression. Mol Cell Biol;26(9):3353-64. 2006-05-01 [PMID: 16611980] (WB, Firefly)
• Petrescu, A et al. Physical and functional interaction of Acyl-CoA-binding protein with hepatocyte nuclear factor-4 alpha. J Biol Chem;278(51):51813-24. 2003-12-19 [PMID: 14530276]
• Wang, X et al. Dynamic tracking of human hematopoietic stem cell engraftment using invivo bioluminescence imaging. Blood;102(10):3478-82. 2003-11-15 [PMID: 12946998] (ICC/IF, Firefly)

Reviews for Luciferase Antibody (NB600-307) (2)

Average Rating: 4.5

(Based on 2 reviews)

We have 2 review tested in 1 species: Rat.

reviewed by: Verified Customer Flow 12/05/2012

Summary

• Application: Flow Cytometry
• Lot: A

reviewed by: Verified Customer WB Rat 04/22/2010

Summary

• Application: Western Blot
• Sample Tested: cardiomyocytes cell lysate, Sample Amount: 15ug
• Species: Rat
• Lot: A

FAQs for Luciferase Antibody (NB600-307). (Showing 1 - 1 of 1 FAQs).

1. Hello. Do you have a specific protocol for use of this antibody in FACS analysis? Luciferase Antibody (Luci 21 1-107) 0.1ml. It is uncojugated, so I am wondering if there is a specific protocol for labeling, etc. Thank you
   • The flow protocol used with this antibody NB600-307 was our general flow protocol. Since this antibody is unconjugated, you would want to use a conjugated mouse IgG secondary with this product in order to detect the antibody. We do also have this specific clone available in a directly conjugated PE form (NB600-307PE). If you are interested, I can inquire about a custom conjugate of another fluor or dye if you like. The other option would be for you to directly conjugate the antibody yourself. We do sell several conjugation kits that are very easy to use.

Bioinformatics

• Uniprot:
  • P08659(Firefly)